natgillin/translations-raw huggingface dataset:
In PROactive, a cardiovascular outcome study, 5238 patients with type 2 diabetes mellitus and preexisting major macrovascular disease were randomised to pioglitazone or placebo in addition to existing antidiabetic and cardiovascular therapy, for up to 3.5 years. 
U PROactive ispitivanju kardiovaskularnih ishoda, 5238 bolesnika sa šećernom bolešću tipa 2 i postojećom teškom makrovaskularnom bolešću bilo je randomizacijom raspodijeljeno u skupinu koja je primala pioglitazon i onu koja je primala placebo uz postojeću antidijabetičku i kardiovaskularnu terapiju u trajanju do 3,5 godine.
Similar changes were seen in metformin (haemoglobin 3-4% and haematocrit 3.6-4.1% relative reductions) and to a lesser extent sulphonylurea and insulin (haemoglobin 1-2% and haematocrit 1-3.2% relative reductions) treated patients in comparative controlled trials with pioglitazone. 
usporednim kontroliranim ispitivanjima pioglitazona opažene su slične promjene u bolesnika liječenih metforminom (relativno smanjenje hemoglobina za 3-4% i hematokrita za 3,6-4,1%) i u manjoj mjeri u bolesnika liječenih sulfonilurejom i inzulinom (relativno smanjenje hemoglobina za 1-2% i hematokrita za 1-3,2%).
In the 3.5 year PROactive study, 44/870 (5.1%) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%) of female patients treated with comparator. 
U PROactive ispitivanju u trajanju od 3,5 godine, 44/870 (5,1%) bolesnica liječenih pioglitazonom doživjelo je prijelom u usporedbi s 23/905 (2,5%; %) bolesnica liječenih usporednim lijekom.
Frequency of adverse reactions of pioglitazone by treatment regimen 
Učestalost nuspojava pioglitazona prema režimu liječenja
An increased incidence in bone fractures in women was seen in a pooled analysis of adverse reactions of bone fracture from randomised, controlled, double blind clinical trials in over 8100 pioglitazone and 7400 comparator treated patients, on treatment for up to 3.5 years. 
Povećana incidencija prijeloma kostiju u žena opažena je u analizi objedinjenih podataka o prijelomima kostiju kao nuspojava u randomiziranim, kontroliranim, dvostruko slijepim kliničkim ispitivanjima na više od 8100 bolesnika liječenih pioglitazonom i 7400 bolesnika liječenih usporednim lijekom u trajanju do najviše 3,5 godine.
1 Postmarketing reports of hypersensitivity reactions in patients treated with pioglitazone have been reported. 
Opis odabranih nuspojava 1Nakon stavljanja lijeka u promet postoje izvještaji o reakcijama preosjetljivosti kod bolesnika liječenih pioglitazonom.
If you stop using Pioglitazone Teva, your blood sugar may go up. 
Pioglitazon Teva, šećer u krvi Vam se može povisiti.
6 In active comparator controlled trials mean weight increase with pioglitazone given as monotherapy was 2-3 kg over one year. 
6 U ispitivanjima kontroliranima aktivnim usporednim lijekom, prosječno povećanje tjelesne težine tijekom monoterapije pioglitazonom iznosilo je 2-3 kg tijekom jedne godine.
4 A pooled analysis was conducted of adverse reactions of bone fractures from randomised, comparator controlled, double blind clinical trials in over 8100 patients in the pioglitazone-treated groups and 7400 in the comparator-treated groups of up to 3.5 years duration. 
4 Provedena je analiza objedinjenih podataka o prijelomima kostiju kao nuspojavama u randomiziranim, usporednim lijekom kontroliranim, dvostruko slijepim kliničkim ispitivanjima u više od 8100 bolesnika u skupinama liječenima pioglitazonom i 7400 bolesnika u skupinama liječenima usporednim lijekom u trajanju do 3,5 godine.
Post-marketing reports of new-onset or worsening diabetic macular oedema with decreased visual acuity have been reported with thiazolidinediones, including pioglitazone. 
U razdoblju nakon stavljanja lijeka u promet zabilježeni su slučajevi novonastalog ili pogoršanja već postojećeg dijabetičkog makularnog edema sa smanjivanjem oštrine vida uz tiazolidindione, uključujući pioglitazon.
Pioglitazone Teva contains pioglitazone. 
Pioglitazon Teva sadrži pioglitazon.
Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with Pioglitazone Teva and insulin experienced the development of heart failure. 
U nekih bolesnika koji su dugo imali šećernu bolest tipa 2 i srčanu bolest ili su preboljeli moždani udar, a liječili su se lijekom Pioglitazon Teva i inzulinom došlo je do zatajenja srca.
- The active substance is pioglitazone. 
- Djelatna tvar je pioglitazon.
In the 3.5 year cardiovascular risk PROactive study, 44/870 (5.1%; 1.0 fractures per 100 patient years) of pioglitazone-treated female patients experienced fractures compared to 23/905 (2.5%; 0.5 fractures per 100 patient years) of female patients treated with comparator. 
U PROactive ispitivanju kardiovaskularnog rizika u trajanju od 3,5 godine, 44/870 (5,1%; 1,0 prijelom na 100 bolesnik-godina) bolesnica liječenih pioglitazonom doživjelo je prijelom u usporedbi s 23/905 (2,5%; 0,5 prijeloma na 100 bolesnik-godina) bolesnica liječenih usporednim lijekom.
If you forget to take Pioglitazone Teva 
Ako ste zaboravili uzeti Pioglitazon Teva
Musculoskeletal and connective tissue disorders fracture bone4 
Poremećaji mišićno-koštanog sustava i vezivnog tkiva prijelom kosti4
What you need to know before you take Pioglitazone Teva Do not take Pioglitazone Teva 
Što morate znati prije nego počnete uzimati Pioglitazon Teva
There have been rare reports of hepatocellular dysfunction during post-marketing experience (see section 4.8). 
Nakon stavljanja lijeka u promet zabilježeni su rijetki slučajevi poremećaja hepatocelularne funkcije (vidjeti dio 4.8).
common (may affect up to 1 in 10 people) - headache - dizziness - joint pain - impotence - back pain - shortness of breath - small reduction in red blood cell count - flatulence uncommon (may affect up to 1 in 100 people) - sugar in urine, proteins in urine - increase in enzymes - spinning sensation (vertigo) - sweating - tiredness - increased appetite 
često (mogu se javiti do 1 od 10 osoba) - glavobolja - omaglica - bol u zglobovima - impotencija - križobolja - nedostatak zraka - manje sniženje broja crvenih krvnih stanica - nadutost manje često (mogu se javiti do 1 od 100 osoba)
There was a small reduction in mean haemoglobin (4% relative reduction) and haematocrit (4.1% relative reduction) during therapy with pioglitazone, consistent with haemodilution. 
(relativno smanjenje za 4%) i hematokrita (relativno smanjenje za 4,1%), sukladno hemodiluciji.
Your weight should be checked at regular intervals; if your weight increases, inform your doctor. 
Ako Vam se tjelesna težina poveća, obavijestite o tome
There was no tumorigenic response in mice of either sex. Hyperplasia of the urinary bladder was not seen in dogs or monkeys treated with pioglitazone for up to 12 months. 
Hiperplazija mokraćnog mjehura nije opažena u pasa i majmuna liječenih pioglitazonom u trajanju do 12 mjeseci.
Localised swelling (oedema) has also been experienced very commonly (may affect more than 1 in 10 people) in patients taking pioglitazone in combination with insulin. 
Lokalizirano oteknuće (edemi) također su vrlo često (mogu se javiti u više od 1 od 10 osoba) nastajali u bolesnika koji su uzimali pioglitazon u kombinaciji s inzulinom.
Pioglitazone Teva 30 mg tablets EU/1/12/757/011-020 
Pioglitazon Teva 30 mg tablete EU/1/12/757/011-020
Pioglitazone Teva 15 mg tablets EU/1/12/757/001-010 
Pioglitazon Teva 15 mg tablete EU/1/12/757/001-010
It is recommended, therefore, that patients treated with pioglitazone undergo periodic monitoring of liver enzymes. 
Stoga se u bolesnika liječenih pioglitazonom preporučuje povremeno određivati jetrene enzime.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. 
U slučaju bilo kakvih nejasnoća ili pitanja u vezi s primjenom ovog lijeka, obratite se svom liječniku ili ljekarniku.
In toxicology studies, plasma volume expansion with haemodilution, anaemia, and reversible eccentric cardiac hypertrophy was consistently apparent after repeated dosing of mice, rats, dogs, and monkeys. 
U toksikološkim ispitivanjima nakon ponavljanja doziranja u miševa, štakora, pasa i majmuna dosljedno su primijećeni povećanje volumena plazme hemodilucijom, anemija i reverzibilna ekscentrična hipertrofija srca.
Pioglitazone Teva 45 mg tablets EU/1/12/757/021-030 
Pioglitazon Teva 45 mg tablete EU/1/12/757/021-030
Pioglitazone Teva 15 mg tablets Pioglitazone Teva 30 mg tablets Pioglitazone Teva 45 mg tablets 
Pioglitazon Teva 15 mg tablete Pioglitazon Teva 30 mg tablete Pioglitazon Teva 45 mg tablete
General disorders and administration site conditions oedema5 
Opći poremećaji i reakcije na mjestu primjene edem5
Bladder cancer has been experienced uncommonly (may affect up to 1 in 100 people) in patients taking pioglitazone. 
Karcinom mokraćnog mjehura manje je često (mogu se javiti do 1 od 100 osoba) nastao u bolesnika koji uzimaju pioglitazon.
How to take Pioglitazone Teva 
Kako uzimati Pioglitazon Teva
Concomitant administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) or with rifampicin (an inducer of cytochrome P450 2C8) is reported to increase or decrease, respectively, the plasma concentration of pioglitazone (see section 4.5). 
Zabilježeno je da istovremena primjena pioglitazona s gemfibrozilom (inhibitor citokroma P450 2C8) povećava, a s rifampicinom (induktor citokroma P450 2C8) snižava koncentracije pioglitazona u plazmi (vidjeti dio 4.5).
Heart failure has been reported with marketing use of pioglitazone, and more frequently when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Zatajenje srca uz primjenu pioglitazona zabilježeno je nakon stavljanja lijeka u promet, i bilo je češće kad se pioglitazon primjenjivao u kombinaciji s inzulinom ili u bolesnika sa zatajenjem srca u anamnezi.
No increase in fracture rates was observed in men treated with pioglitazone (1.3%) versus comparator (1.5%). 
Nije bilo primijećeno povećanje stopa prijeloma u muškaraca liječenih pioglitazonom (1,3%) u odnosu na usporedni lijek (1,5%).
Adverse reactions reported in excess (> 0.5%) of placebo and as more than an isolated case in patients receiving pioglitazone in double-blind studies are listed below as MedDRA preferred term by system organ class and absolute frequency. 
Tablični prikaz nuspojava Nuspojave koje su bile zabilježene češće (> 0,5%) nego uz placebo ili kao izolirani slučaj u bolesnika koji su primali pioglitazon u dvostruko slijepim ispitivanjima navedene su niže prema MedDRA
31-546, Krakow Poland 
Teva Operations Poland Sp z.o.o. ul. Mogilska 80. 31-546, Krakow Poljska
A higher rate of fractures was observed in women taking pioglitazone (2.6%) versus comparator (1.7%). 
Viša stopa prijeloma bila je primijećena u žena koje su uzimale pioglitazon (2,6%) u odnosu na usporedni lijek (1,7%).
How to store Pioglitazone Teva 
Kako čuvati Pioglitazon Teva
Carmellose calcium Hydroxypropylcellulose Magnesium stearate 
6.1 Popis pomoćnih tvari manitol karmelozakalcij hidroksipropilceluloza magnezijev stearat
Your doctor will ask you to have blood tests periodically during treatment with Pioglitazone Teva. 
Liječnik će tražiti da za vrijeme liječenja lijekom Pioglitazon Teva povremeno napravite krvne pretrage, da bi se provjerilo radi li Vaša jetra normalno.
Nervous system disorders hypo-aesthesia common common common common common headache common uncommon dizziness common insomnia uncommon uncommon uncommon uncommon uncommon 
Poremećaji živčanog sustava hipoestezija glavobolja manje često omaglica nesanica manje često manje često manje često manje često manje često
Pioglitazone 
Nuspojava
No increase in fracture rates was observed in men treated with pioglitazone (1.7%) versus comparator (2.1%). 
Nije bilo primijećeno povećanje stopa prijeloma u muškaraca liječenih pioglitazonom (1,7%) u odnosu na one liječene usporednim lijekom (2,1%).
There have been post-marketing cases of cardiac failure reported when pioglitazone was used in combination with insulin or in patients with a history of cardiac failure. 
Nakon stavljanja lijeka u promet zabilježeni su slučajevi zatajenja srca kad se pioglitazon primjenjivao u kombinaciji s inzulinom i u bolesnika sa zatajenjem srca u anamnezi.
Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema). 
Ako razvijete znakove zatajenja srca kao što su neuobičajeni nedostatak zraka, brzo povećanje tjelesne težine ili lokalizirana nateknuća (edemi), čim prije obavijestite o tome svog liječnika.
A higher number of bone fractures was seen in patients, particularly women taking pioglitazone. 
U bolesnika, naročito u žena koje uzimaju pioglitazon primijećen je povećan broj prijeloma kostiju.
Teva Pharmaceutical Works Private Limited Company Pallagi út 13 
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet Teva Pharmaceutical Works Private Limited Company Pallagi út 13
You can usually continue to take other medicines whilst you are being treated with Pioglitazone Teva. 
Za vrijeme liječenja lijekom Pioglitazon Teva obično možete nastaviti uzimati druge lijekove.
not known (frequency cannot be estimated from the available data) - increase in liver enzymes - allergic reactions 
- povišenje vrijednosti jetrenih enzima - alergijske reakcije
Cardiac disorders heart failure3 
Srčani poremećaji zatajenje srca3
- Pioglitazone Teva 45 mg tablets are white to off white, round, convex with the number ‘45' on one side and ‘TEVA' on the other side. 
- Pioglitazon Teva 45 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘45' na jednoj strani i ‘TEVA' na drugoj.
- Pioglitazone Teva 30 mg tablets are white to off white, round, convex with the number ‘30' on one side and ‘TEVA' on the other side. 
- Pioglitazon Teva 30 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘30' na jednoj strani i ‘TEVA' na drugoj.
Österreich ratiopharm Arzneimittel Vertriebs-GmbH Tel: +43 1 97 0070 
Österreich ratiopharm Arzneimittel Vertriebs-GmbH
Read the package leaflet before use. 
NAČIN I PUT(EVI) PRIMJENE LIJEKA Prije uporabe pročitajte Uputu o lijeku.
There may be an increased possibility of becoming pregnant because you may ovulate again when you take Pioglitazone Teva. 
Kad uzimate Pioglitazon Teva možete ponovno imati ovulaciju pa mogućnost trudnoće može biti povećana.
Teva UK Ltd Brampton Road, Hampden Park, Eastbourne, 
Brampton Road, Hampden Park, Eastbourne, East Sussex, BN22 9AG Ujedinjeno Kraljevstvo
Infections and infestations upper respiratory tract infection common common common common common bronchitis common sinusitis uncommon uncommon uncommon uncommon uncommon 
Infekcije gornjih dišnih puteva bronhitis sinusitis manje često manje često manje često manje često manje često
- in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance as dual oral therapy in combination with - metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin - a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea as triple oral therapy in combination with 
- u odraslih bolesnika (osobito bolesnika s prekomjernom tjelesnom težinom) u kojih se kontrola ne postiže dijetom i tjelovježbom i u kojih metformin nije prikladan zbog kontraindikacija ili nepodnošenja kao dvojna peroralna terapija u kombinaciji s
- Pioglitazone Teva 15 mg tablets are white to off white, round, convex with the number ‘15' on one side and ‘TEVA' on the other side. 
- Pioglitazon Teva 15 mg tablete su bijele do gotovo bijele boje, okrugle, konveksne, s oznakom ‘15' na jednoj strani i ‘TEVA' na drugoj.
However, certain medicines are especially likely to affect the amount of sugar in your blood: - gemfibrozil (used to lower cholesterol) - rifampicin (used to treat tuberculosis and other infections) Tell your doctor or pharmacist if you are taking any of these. 
- rifampicin (primjenjuje se za liječenje tuberkuloze i drugih infekcija) Obavijestite svog liječnika ili ljekarnika ako uzimate te lijekove.
Respiratory, thoracic and mediastinal disorders dyspnoea common 
Poremećaji dišnog sustava, prsišta i sredoprsja dispneja
Pioglitazone Teva 45 mg tablets 
Pioglitazon Teva 45 mg tablete
Blurred vision due to swelling (or fluid) at the back of the eye (frequency cannot be estimated from the available data) has also been reported in patients taking pioglitazone. 
U bolesnika koji uzimaju pioglitazon zabilježen je i zamagljen vid zbog oticanja (ili tekućine) stražnje strane oka (učestalost se ne može procijeniti iz dostupnih podataka).
Each Pioglitazone Teva 30 mg tablet contains 30 mg of pioglitazone (as hydrochloride). 
Jedna tableta lijeka Pioglitazon Teva od 30 mg sadrži 30 mg pioglitazona (u obliku pioglitazonklorida).
Pioglitazone Teva 30 mg tablets 
Pioglitazon Teva 30 mg tablete
Ear and labyrinth disorders vertigo uncommon 
Poremećaji uha i labirinta vrtoglavica manje često
Pioglitazone Teva 45 mg tablets Pioglitazone 
Pioglitazon Teva 45 mg tablete pioglitazon
This is to check that your liver is working normally. 
Trebate provjeravati tjelesnu težinu u redovitim vremenskim razmacima.
Each Pioglitazone Teva 45 mg tablet contains 45 mg of pioglitazone (as hydrochloride). 
Jedna tableta lijeka Pioglitazon Teva od 45 mg sadrži 45 mg pioglitazona (u obliku pioglitazonklorida).
No dose adjustment is necessary in patients with impaired renal function (creatinine clearance > 4 ml/min) (see section 5.2). 
> 4 ml/min) (vidjeti dio 5.2).
Each tablet contains 45 mg pioglitazone (as hydrochloride). 
Jedna tableta sadrži 45 mg pioglitazona (u obliku pioglitazonklorida).
Pioglitazone Teva 30 mg tablets Pioglitazone 
Pioglitazon Teva 30 mg tablete pioglitazon
Pioglitazone Teva 15 mg tablets 
Pioglitazon Teva 15 mg tablete
Each tablet contains 30 mg pioglitazone (as hydrochloride). 
Jedna tableta sadrži 30 mg pioglitazona (u obliku pioglitazonklorida).
The other side effects that have been experienced by some patients when pioglitazone is taken with other antidiabetic medicines are: 
Druge nuspojave koje su neki bolesnici osjetili kod uzimanja pioglitazona s drugim antidijabetičkim lijekovima su: vrlo često (mogu se javiti u više od 1 od 10 osoba)
If you experience any of these, talk to your doctor as soon as possible. 
Ako primijetite ovu nuspojavu, čim prije razgovarajte s Vašim liječnikom.
- diabetic ketoacidosis - current bladder cancer or a history of bladder cancer - uninvestigated macroscopic haematuria 
- oštećenjem funkcije jetre - dijabetičkom ketoacidozom - postojećim ili preboljenim karcinomom mokraćnog mjehura
Co-administration of pioglitazone with rifampicin (an inducer of cytochrome P450 2C8) is reported to result in a 54% decrease in AUC of pioglitazone. 
Zabilježeno je da istodobna primjena pioglitazona s rifampicinom (induktor citokroma P450 2C8) rezultira smanjenjem
Metabolism and nutrition disorders hypo-glycaemia uncommon very common 
Poremećaji metabolizma i prehrane hipoglikemija manje često vrlo često pojačan apetit manje često
The tablets are white to off-white, round, convex and debossed with the number ‘45' on one side and ‘TEVA' on the other side. 
Tablete su bijele do gotovo bijele boje, okrugle, konveksne i imaju oznaku ‘45' s jedne strane i ‘TEVA' s druge strane.
Each Pioglitazone Teva 15 mg tablet contains 15 mg of pioglitazone (as hydrochloride). 
Jedna tableta lijeka Pioglitazon Teva od 15 mg sadrži 15 mg pioglitazona (u obliku pioglitazonklorida).
Each tablet contains 15 mg pioglitazone (as hydrochloride). 
Jedna tableta sadrži 15 mg pioglitazona (u obliku pioglitazonklorida).
Pioglitazone Teva 15 mg tablets Pioglitazone 
Pioglitazon Teva 15 mg tablete pioglitazon
The tablets are white to off-white, round, convex and debossed with the number ‘30' on one side and ‘TEVA' on the other side. 
Tablete su bijele do gotovo bijele boje, okrugle, konveksne i imaju oznaku ‘30' s jedne strane i ‘TEVA' s druge strane.
In most clinical trials, reduced total plasma triglycerides and free fatty acids, and increased HDLcholesterol levels were observed as compared to placebo, with small, but not clinically significant increases in LDL-cholesterol levels. 
HDL-kolesterola u usporedbi s placebom, uz mala ali ne i klinički značajna povišenja razine LDL
Marketing Authorisation Holder: 
Nositelj odobrenja za stavljanje gotovog lijeka u promet:
nausea or vomiting). 
- osjećaj vrtnje (vrtoglavica)
If you experience this side effect, talk to your doctor as soon as possible. 
Ako razvijete ovu nuspojavu, čim prije razgovarajte s Vašim liječnikom.
very common (may affect more than 1 in 10 people) - decreased blood sugar (hypoglycaemia) 
- utrnulost manje često (mogu se javiti do 1 od 100 osoba) - upala sinusa (sinusitis)
It is not known whether pioglitazone is secreted in human milk. 
Nije poznato izlučuje li se pioglitazon u majčino mlijeko u ljudi pa se stoga pioglitazon ne smije primjenjivati u dojilja.
The observed excess risk of fractures for women in this dataset on pioglitazone is therefore 0.8 fractures per 100 patient years of use. 
Opaženo povećanje rizika od prijeloma u žena u ovom sklopu podataka o pioglitazonu stoga iznosi
Mon. Tue. 
- znojenje - umor
The tablets are white to off-white, round, convex and debossed with the number ‘15' on one side and ‘TEVA' on the other side. 
Tablete su bijele do gotovo bijele boje, okrugle, konveksne i imaju oznaku ‘15' s jedne strane i ‘TEVA' s druge strane.
Rare cases of elevated liver enzymes and hepatocellular dysfunction have occurred in post-marketing experience. 
Nakon stavljanja lijeka u promet bilo je rijetkih slučajeva povišenih jetrenih enzima i poremećaja funkcije jetre.
България Тева Фармасютикълс България ЕООД 
UAB “Sicor Biotech” Eesti filiaal
Neoplasms benign, malignant and unspecified (including cysts and polyps) 
Dobroćudne, zloćudne i nespecificirane novotvorine
Tel: +421 2 57 26 79 11 
TEVA Pharmaceuticals Slovakia s.r.o. Tel: +421 2 57 26 79 11
Co-administration of pioglitazone with gemfibrozil (an inhibitor of cytochrome P450 2C8) is reported to result in a 3-fold increase in AUC of pioglitazone. 
Zabilježeno je da istodobna primjena pioglitazona s gemfibrozilom (inhibitor citokroma P450 2C8)
common (may affect up to 1 in 10 people) - respiratory infection - abnormal vision - weight gain - numbness uncommon (may affect up to 1 in 100 people) - inflammation of the sinuses (sinusitis) - difficulty sleeping (insomnia) 
Ostale nuspojave koje su osjetili neki bolesnici koji uzimaju pioglitazon su: često (mogu se javiti do 1 od 10 osoba) - infekcija dišnih putova - abnormalni vid
Pliva Hrvatska d.o.o. 
artralgija križobolja
Patients should be observed for signs and symptoms of heart failure, weight gain and oedema when pioglitazone is used in combination with insulin. 
Kad se pioglitazon primjenjuje u kombinaciji s inzulinom, bolesnike treba nadzirati zbog znakova i simptoma zatajenja srca, povećanja tjelesne težine i pojave edema.
Renal and urinary disorders haematuria common glycosuria uncommon proteinuria uncommon 
Poremećaji bubrega i mokraćnog sustava hematurija glikozurija manje često proteinurija manje često
It is especially important to mention these: 
Osobito je važno da spomenete sljedeće:
Your doctor will test for these changes. 
Vaš liječnik će obaviti provjere u vezi tih promjena.
Your child's doctor will decide this. 
To će odlučiti liječnik Vašeg djeteta.
Date of first authorisation: 22 August 2016 
Datum prvog odobrenja: 22 kolovoz 2016
During the second and third trimesters of pregnancy 
Tijekom drugog i trećeg tromjesečja trudnoće
15 to less than 35 
15 do manje od 35
These could be symptoms of a serious heart problem. 
To mogu biti simpotmi ozbiljnog srčanog problema.
Such changes may in part be linked to the disease control and life style. 
Te promjene mogu biti djelomično povezane s kontrolom bolesti i stilom života.